Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT00410605Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate up to 5 years. Started Nov 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00410605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410605.